To further dissect the genetic architecture of colorectal cancer (CRC), we performed whole-genome sequencing of 1,439 cases and 720 controls, imputed discovered sequence variants and Haplotype Reference Consortium panel variants into genomewide association study data, and tested for association in 34,869 cases and 29,051 controls. Findings were followed up in an additional 23,262 cases and 38,296 controls. We discovered a strongly protective 0.3% frequency variant signal at CHD1. In a combined meta-analysis of 125,478 individuals, we identified 40 new independent signals at P < 5 × 10
C olorectal cancer (CRC) is the fourth leading cancer-related cause of death worldwide 1 and presents a major public health burden. Up to 35% of interindividual variability in CRC risk has been attributed to genetic factors 2, 3 . Family-based studies have identified rare high-penetrance mutations in at least a dozen genes, but collectively, these account for only a small fraction of familial risk 4 . Over the past decade, genome-wide association studies (GWASs) for sporadic CRC, which constitutes the majority of cases, have identified ~60 association signals at over 50 loci [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . Yet most of the genetic factors contributing to CRC risk remain undefined. This severely hampers our understanding of biological processes underlying CRC. It also limits CRC precision prevention, including individualized preventive screening recommendations and development of cancer prevention drugs. The contribution of rare variation to sporadic CRC is particularly poorly understood.
To expand the catalog of CRC risk loci and improve our understanding of rare variants, genes and pathways influencing sporadic CRC risk and risk prediction, we performed the largest and most comprehensive whole-genome sequencing (WGS) study and GWAS meta-analysis for CRC so far, combining data from three consortia: the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), the Colorectal Cancer Transdisciplinary Study (CORECT) and the Colon Cancer Family Registry (CCFR). Our study almost doubles the number of individuals analyzed, incorporating GWAS results from > 125,000 individuals, and substantially expands and strengthens our understanding of biological processes underlying CRC risk.
Results
Study overview. We performed WGS of 1,439 CRC cases and 720 controls of European ancestry at low sequencing depth (3.8-8.6× ). We detected, called and estimated haplotype phase for 31.8 million genetic variants, including 1.7 million short insertion-deletion variants (indels) (Methods). These data include many rare variants not studied by GWAS. As other large-scale WGS studies have used a similar design, we expected to have near-complete ascertainment of single-nucleotide variants with minor allele count (MAC) > 5 (minor allele frequency (MAF) > 0.1%), and high accuracy at heterozygous genotypes 23, 24 . We tested 14.4 million variants with MAC ≥ 5 for CRC association using logistic regression (Methods) but did not find any significant associations. To increase power to detect associations with rare and low-frequency variants of modest effect, we imputed variants from the sequencing experiment into 34,869 cases and 29,051 controls of predominantly European (91.7%) and East Asian ancestry (8.3%) from 30 existing GWASs (Methods and Supplementary Table 1) . By design, two-thirds of sequenced individuals were CRC cases, thereby enriching the panel for rare or low-frequency alleles that increase CRC risk. We contributed our sequencing data to the Haplotype Reference Consortium (HRC) 25 and imputed the 30 existing GWASs to the HRC panel, which comprises haplotypes for 32,488 individuals. Results of these GWAS meta-analyses (referred to as stage 1 meta-analysis; Methods) informed the design of a custom Illumina array comprising the OncoArray, a custom array to identify cancer risk loci 26 , and 15,802 additional variants selected based on stage 1 meta-analysis results. We genotyped 12,007 cases and 12,000 controls of European ancestry with this custom array, and combined them with an additional 11,255 cases and 26,296 controls with GWAS data, resulting in a stage 2 meta-analysis of 23,262 CRC cases and 38,296 controls (Methods, Supplementary Fig. 1 and Supplementary Table 1) . Next, we performed a combined (stage 1 + stage 2) meta-analysis of up to 58,131 cases and 67,347 controls. This meta-analysis was based on the HRC panel-imputed data because, given its large size, this panel results in superior imputation quality and enables accurate imputation of variants with MAFs as low as 0.1% (ref. 25 ). Here, we report new association signals discovered through our custom genotyping experiment and replicated in stage 2 at the Bonferroni significance threshold of P < 7.8 × 10 −6 (Methods), as well as distinct association signals passing the genome-wide significance (GWS) threshold of P < 5 × 10 −8 in the combined meta-analysis of up to 125,478 individuals. 5q21.1, near genes CHD1 and RGMB. SNP rs145364999, which is intronic to CHD1, had high-quality genotyping ( Supplementary  Fig. 4 ). The variant was well imputed in the remaining sample sets (imputation quality r 2 of 0.66-0.87; Supplementary Table 2 ) and there was no evidence of heterogeneity of effects (heterogeneity P = 0.63; Supplementary Table 2) . The rare allele confers a strong protective effect (allelic odds ratio (OR) = 0.52 in stage 2; 95% confidence interval (CI) = 0.40-0.68). Chromatin remodeling factor CHD1 provides an especially plausible candidate and is a synthetically essential gene 27 that is occasionally deleted in some cancers, but always retained in PTEN-deficient cancers 28 . The resulting mutually exclusive deletion pattern of CHD1 and PTEN has been observed in prostate, breast and CRC The Cancer Genome Atlas data 28 . We hypothesize that the rare allele confers a protective effect by lowering CHD1 expression, which is required for nuclear factor-κ β (NF-κ β ) pathway activation and growth in cancer cells driven by loss of the tumor suppressor gene PTEN 28 . However, we cannot rule out involvement of nearby candidate gene RGMB that encodes a co-receptor for bone morphogenetic proteins BMP2 and BMP4, both of which are linked to CRC risk through GWAS 9, 11 . Additionally, RGMB binds to PD-L2 (ref. 29 ), a known ligand of PD-1, an immune checkpoint blockade receptor targeted by cancer immunotherapy 30 . The vast majority of new association signals involve common variants. We found associations near strong candidate genes for CRC risk in pathways or gene families not previously implicated by GWAS. Locus 13q22.1, represented by lead SNP rs78341008 (MAF 7.2%; P = 3.2 × 10 −10 ), is near KLF5, a known CRC oncogene that can be activated by somatic hotspot mutations or super-enhancer duplications 31, 32 . KLF5 encodes transcription factor Krüppel-like factor 5 (KLF5), which promotes cell proliferation and is highly expressed in intestinal crypt stem cells. We also found an association at locus 19p13.11, near KLF2. KLF2 expression in endothelial cells is critical for normal blood vessel function 33, 34 . Downregulated KLF2 expression in colon tumor tissues contributes to structurally and functionally abnormal tumor blood vessels, leading to impaired blood flow and hypoxia in tumors 35 . Another locus at 9q31.1 is near LPAR1, which encodes a receptor for lysophosphatidic acid (LPA). LPA-induced expression of hypoxia-inducible factor 1 (HIF-1α ), a key regulator of cellular adaptation to hypoxia and tumorigenesis, depends on KLF5 (ref.
36
). Additionally, LPA activates multiple signaling pathways and stimulates proliferation of colon cancer cells by activation of KLF5 (ref.
37
). Another locus (7p13) is near SNHG15, which encodes a long noncoding RNA (lncRNA) that epigenetically represses KLF2 to promote pancreatic cancer proliferation 38 . We found two loci near members of the Hedgehog (Hh) signaling pathway. Aberrant activation of this pathway, caused by somatic mutations or changes in expression, can drive tumorigenesis in many tumors 39 . Notably, downregulated stromal cell Hh signaling accelerates colonic tumorigenesis in mice 40 . Locus 3q13.2, represented by low-frequency lead SNP rs72942485 (MAF 2.2%; P = 2.1 × 10
), overlaps with BOC, which encodes a Hh coreceptor molecule. In medulloblastoma, upregulated BOC promotes Hh-driven tumor progression through cyclin D1-induced DNA damage 41 . In pancreatic cancer, a complex role for stromal BOC expression in tumorigenesis and angiogenesis has been reported 42 . Locus 4q31.21 is near HHIP, which encodes an inhibitor of Hh signaling. Notably, the Hh signaling pathway was also significantly enriched in our pathway analysis (described below).
Locus 11q22.1 is near YAP1, which encodes a critical downstream regulatory target in the Hippo signaling pathway that is gaining recognition as a pivotal player in organ size control and tumorigenesis 43 . YAP1 is highly expressed in intestinal crypt stem cells, and in transgenic mice, its overexpression led to severe intestinal dysplasia and loss of differentiated cell types 44 , reminiscent of phenotypes observed in mice and humans with deleterious germline APC mutations. Further, hypoxia-inducible factor 2α (HIF-2α ) promotes colon cancer growth by upregulating YAP1 activity 45 . We provide further evidence for a link between immune function and CRC pathogenesis, and implicate the major histocompatibility complex (MHC) in CRC risk. We identified a locus near genes HLA-DRB1 and HLA-DQA1 that is associated with immunemediated diseases 46 . We identified two new loci near known tumor suppressor genes. Locus 4q24 is near TET2, a chromatin-remodeling gene that is frequently somatically mutated in multiple cancers, including colon cancer 47 , and that overlaps with GWAS signals for multiple other cancers [48] [49] [50] . The CDKN2B-CDKN2A-ANRIL (CDKN2B-AS1) locus at 9p21.3 is a well-established hotspot of pleiotropic GWAS associations for many complex diseases, including coronary artery disease 51 , type 2 diabetes 52 and cancers 50, [53] [54] [55] [56] . Notably, lead variant rs1537372 is in high LD (r 2 = 0.82) with variants associated with coronary artery disease 51 and endometriosis 57 , but not with the other cancer-associated variants. CDKN2A and CDKN2B encode cyclin-dependent kinase (CDK) inhibitors that regulate the cell cycle. CDKN2A is one of the most commonly inactivated genes in cancer, and is a high penetrance gene for melanoma 58, 59 . CDKN2B activation is tightly controlled by the cytokine TGF-β , further linking this signaling pathway with CRC tumorigenesis 60 . Our findings implicate genes in pathways with established roles in CRC pathogenesis. We identified loci at SMAD3 and SMAD9, members of the TGF-β signaling pathway, which includes genes linked to familial CRC syndromes (for example, SMAD4 and BMPR1A) and several GWAS-implicated genes (for example, SMAD7, BMP2 and BMP4) 61 . We identified another locus near TGF-β receptor 1 (TGFBR1). Nearby gene GALNT12 harbors inactivating germline and somatic mutations in human colon cancers 62 and therefore could also be the regulated effector gene. We identified a locus at 14q23.1 near DACT1, a member of the Wnt-β -catenin pathway which includes genes previously linked to familial CRC syndromes (APC 63 ), and several GWAS-implicated genes (for example, CTNNB1 18 and TCF7L2
17
). Genes related to telomere biology were linked by other GWASs: TERC 10 and TERT
22
, which encode the RNA and protein subunits of telomerase, respectively, and FEN1 (ref. 17 ), which is involved in telomere stability 64 . A new locus at 20q13.33 harbors another gene related to telomere biology, RTEL1. This gene is involved in DNA double-strand-break repair, and overlaps with GWAS signals for cancers 55, 65 and inflammationrelated phenotypes, including inflammatory bowel disease 66 and atopic dermatitis 67 . Of 61 signals at 56 loci previously associated with CRC at GWS, 42 showed association evidence at P < 5 × 10 −8 in the combined meta-analysis, and 55 at P < 0.05 in the independent stage 2 meta-analysis (Supplementary Table 3) . Notably, the association of rs755229494 at locus 5q22.2 (P = 2.1 × 10
) was driven by studies of predominantly subjects with Ashkenazi Jewish ancestry, and this SNP is in perfect LD with known missense SNP rs1801155 in the APC gene (p.Ile1307Lys), the minor allele of which is enriched in this population (MAF 6%), but rare in other populations 68, 69 .
Delineating distinct association signals at CRC risk loci. To identify additional independent association signals at known or new CRC risk loci, we conducted conditional analysis using individual-level data of 125,478 participants (Methods). At nine loci, we observed ten new independent association signals that attained a P value in a joint multiple-variant analysis (P J ) < 5 × 10 −8 (Table 2,  Supplementary Table 4 and Supplementary Fig. 5 ). Because this analysis focused on < 5% of the genome, we also report signals at P J < 1 × 10 −5 in Supplementary Table 5 . At 22 loci, we observed 25 new suggestive associations with P J < 1 × 10
. At locus 11q13.4, near POLD3 and CHRDL2, we identified a new low-frequency variant (lead SNP rs61389091, MAF 3.94%) separated by a recombination hotspot from the known common variant signal 12 (LD r 2 between lead SNPs < 0.01). At 5p15.33, we identified another lower-frequency variant association (lead SNP rs78368589, MAF 5.97%), which was independent from the previously reported common variant signal 56 kb away, near TERT and CLPTM1L (LD r 2 with lead SNP rs2735940 < 0.01) 22 . Variants in this region were linked to many cancer types, including lung, prostate, breast and ovarian cancer 70 . The remaining eight new signals involved common variants. At new locus 2q33.1, near genes PLCL1 and SATB2, two statistically independent associations (LD r 2 between two lead SNPs < 0.01) are separated by a recombination hotspot ( Supplementary Fig. 5 ). In the MHC region, we identified a conditionally independent signal near genes involved in NF-κ β signaling, including the gene encoding tumor necrosis factor-α , genes for the stress-signaling proteins MICA and MICB, and HLA-B. Locus 20p12.3, near BMP2, harbored four distinct association signals (Fig. 1) , two of which have been reported 10, 11 (Supplementary Table 5 ). All four SNPs selected in the model were in pairwise linkage equilibrium (maximum LD r 2 = 0.039, between rs189583 and rs994308). Our conditional analysis further confirmed that the signal ~1-Mb centromeric of BMP2, near gene HAO1, is independent. At locus 8q24.21 near MYC, the locus showing the second strongest statistical evidence of association in the combined meta-analysis (lead SNP rs6983267; P = 3.4 × 10 ), we identified a second independent signal (lead SNP rs4313119, P J = 2.1 × 10
; LD r 2 with rs6983267 < 0.001). At the recently reported locus 5p13.1 (ref. 22 ), near the noncoding RNA gene LINC00603, we identified an additional signal (lead SNP rs7708610) that was partly masked by the reported signal in the single-variant analysis due to the negative correlation between rs7708610 and rs12514517 (r = − 0.18; r 2 = 0.03). This caused significance for both SNPs to increase markedly when fitted jointly (rs7708610, unconditional P = 1.5 × 10 −5 and P J = 3.8 × 10
−9
). At locus 12p13.32 near CCND2, we identified a new signal (lead SNP rs3217874, P J = 2.4 × 10 −9 ) and confirmed two previously associated signals [13] [14] [15] (Supplementary Note). At the GREM1 locus on 15q13.3, two independent signals have been described , conditioned on rs2293581 and rs12708491; LD with conditioning SNPs r 2 < 0.01; Supplementary Note). Additionally, signals with P J values approaching GWS were observed at new locus 3q13.2 near BOC (rs13086367, unconditional P = 6.7 × 10 Table 5 ). Furthermore, we clarified previously reported independent association signals (Supplementary Note).
Associations of CRC risk variants with other traits. Some 19 of the GWS association signals for CRC were in high LD (r 2 > 0.7) Lead variant is the most associated variant at the locus in the conditional analysis. Reference SNP cluster ID (rsID) based on NCBI dbSNP Build 150. Alleles are on the + strand. Chr., chromosome; RAF, risk allele frequency, based on stage 2 data; OR, odds ratio estimates are for the risk allele. Conditioning variants are the lead variant of other conditionally independent association signals with P < 1 × 10 −5 within 1 Mb of the new association signal. Because of extensive LD, we used a 2-Mb distance for the MHC region (6p21.32). All lead variants for the new association signals are in linkage equilibrium with any previously reported CRC risk variants at the locus (r 2 < 0.10). a Conditioning variant is either the index variant, or a variant in LD with the index variant reported in previous GWAS. Details and full results are in Supplementary Table 5 .
with at least one SNP in the NHGRI-EBI GWAS Catalog 46 that has significant association in GWASs of other traits. Notable overlap included SNPs associated with other cancers, immune-related traits (for example, tonsillectomy, inflammatory bowel disease and circulating white blood cell traits), obesity traits, blood pressure and other cardiometabolic traits (Supplementary Table 6 ).
Mechanisms underlying CRC association signals.
To further localize variants driving the 40 newly identified signals, we used association evidence to define credible sets of variants that are 99% probable to contain the causal variant (Methods). The 99% credible set size for new loci ranged from one (17p12) to 93 (2q33.1). For 11 distinct association signals, the set included ten or fewer variants (Supplementary Table 7) . At locus 17p12, we narrowed the candidate variant to rs1078643, located in exon 1 of the lncRNA LINC00675, which is primarily expressed in gastrointestinal tissues. Small credible sets were observed for locus 4q31.21 (two variants, indexed by synonymous SNP rs11727676 in HHIP), and signals at known loci near GREM1 (one variant) and CCND2 (two variants).
We performed functional annotation of credible set variants to nominate putative causal variants. Eight sets contained coding variants, but only the synonymous SNP in HHIP had a high posterior probability of driving the association (Supplementary Table 8 ). Next, we examined overlap of credible sets with regulatory genomic annotations from 51 existing CRC-relevant data sets to examine noncoding functions (Methods). Also, to better refine regulatory elements in active enhancers, we performed the assay for transposase-accessible chromatin using sequencing (ATAC-seq) to measure chromatin accessibility in four colonic crypts and used the resulting data to annotate GWAS signals.
Of the 40 sets, 36 overlapped with active enhancers identified by histone mark H3K27ac, which was measured in normal colonic crypt epithelium, CRC cell lines or CRC tissue (Supplementary Table 8 and Supplementary Fig. 6 ). Twenty of these 36 sets overlapped with super-enhancers. Notably, when compared with epigenomics data from normal colonic crypt epithelium, all 36 sets overlapped with enhancers that gained or lost activity in one or more CRC specimens. Eleven of these sets overlapped with enhancers that recurrently gained or lost activity in ≥ 20 CRC cell lines.
The locus at GWAS hotspot 9p21 overlaps with a superenhancer, and the credible set is entirely intronic to ANRIL, alias CDKN2B-AS1. The Genotype-Tissue Expression (GTEx) data show that the antisense lncRNA ANRIL is exclusively expressed in transverse colon and small intestine. Notably, ANRIL recruits SUZ12 and EHZ2 to epigenetically silence tumor suppressor genes CDKN2A and CDKN2B
71
. Noncoding somatic driver mutations or focal amplifications have been reported in regions regulating expression of MYC 72 , TERT 73 and KLF5 (ref.
31
), which are now implicated by GWAS for CRC. We checked whether GWAS-identified association signals colocalize with these regions and found that the KLF5 signal overlaps with the somatically amplified super-enhancer flanked by KLF5 and KLF12 (Fig. 2) . Also, the previously reported signal in the TERT promoter region 22 overlaps with the recurrent somatically mutated region in multiple cancers 73 .
To test whether CRC associations are nonrandomly distributed across genomic features, we used GARFIELD 74 . Focusing on DNase I hypersensitive site peaks that identify open chromatin, we observed significant enrichment across many cell types, particularly fetal tissues, with the strongest enrichment observed in fetal gastrointestinal tissues, CD20
+ primary cells (B cells) and embryonic stem cells ( Supplementary Fig. 7 and Supplementary Table 9) .
We used MAGENTA 75 to identify pathways or gene sets enriched for associations with CRC, assessing two gene P-value cutoffs: the lifetime risk of 4.3%, we estimated that all imputed autosomal variants explain 21.6% (95% CI = 17.5-25.7%) of the variation in liability for CRC, with almost half of this contributed by rare variants (h g 2 = 9.7%, 95% CI = 6.2-13.3%; likelihood ratio test P = 0.003); the estimated liability-scale heritability for variants with MAF > 1% is 11.8% (95% CI = 8.9-14.7%). Our overall estimate falls within the range of heritability reported by large twin studies 2 . Because heritability estimates for rare variants are sensitive to potential biases due to technical effects or population stratification 77 , and the contribution of rare variants is probably underestimated due to limitations of genotype imputation, the results should be interpreted with caution. Overall, the findings suggest that missing heritability is not large, but that many rare and common variants have yet to be identified.
Familial relative risk explained by GWAS-identified variants.
Adjusting for the winner's curse 78 , the familial relative risk (RR) to first-degree relatives (λ 0 ) attributable to GWAS-identified variants rose from 1.072 for the 55 previously described autosomal risk variants that showed evidence for replication at P < 0.05, to 1.092 after inclusion of 40 new signals, and increased further to 1.098 when we included 25 suggestive association signals reported in Supplementary Table 5 (Methods). Assuming a λ 0 of 2.2, the 55 established signals account for 8.8% of familial RR explained (95% CI = 8.1-9.4). Established signals combined with 40 newly discovered signals account for 11.2% (95% CI = 10.5-12.0), and adding 25 suggestive signals increases this to 11.9% (95% CI = 11.1-12.7).
Implications for stratified screening prevention. We demonstrate how using a polygenic risk score (PRS) derived from 95 independent association signals could affect clinical guidelines for preventive screening. The difference in recommended starting age for screening for those in the highest 1% (and 10%) percentiles of risk compared with lowest percentiles is 18 years (and 10 years) for men, and 24 years (and 12 years) for women ( Fig. 3; Methods) . Supplementary Table 11 gives risk allele frequency estimates in different populations for variants included in the PRS. As expected, risk allele frequencies vary across populations. Furthermore, differences in LD between tagging and true causal variants across populations can lead to less prediction accuracy and subsequent lower predictive power of the PRS in non-European populations. Accordingly, it will be important to develop ancestry-specific PRSs that incorporate detailed fine-mapping results for each GWAS signal.
Discussion
To further define the genetic architecture of sporadic CRC, we performed low-coverage WGS and imputation into a large set of GWAS data. We discovered 40 new CRC signals and replicated 55 previously reported signals. We found the first rare variant signal for sporadic CRC, which represents the strongest protective rare allelic effect identified so far. Our analyses highlight new genes and pathways contributing to underlying CRC risk and suggest roles for Krüppel-like factors, Hedgehog signaling, Hippo-YAP signaling and immune function. Multiple loci provide new evidence for an important role of lncRNAs in CRC tumorigenesis 79 . Functional genomic annotations support that most of the sporadic CRC genetic risk lies in noncoding genomic regions. We further show how newly discovered variants can lead to improved risk prediction.
This study underscores the critical importance of large-scale GWAS collaboration. Although discovery of the rare variant signal was possible only through increased coverage and improved imputation accuracy enabled by imputation panels, sample size was pivotal for discovery of new CRC loci. The results suggest that CRC has a highly polygenic architecture, much of which remains undefined. This also suggests that continued GWAS efforts, together with increasingly comprehensive imputation panels that allow for improved low-frequency and rare genetic variant imputation, will uncover more CRC risk variants. In addition, to investigate sites that are not imputable, large-scale deep sequencing will be needed. Importantly, the prevailing European bias in CRC GWASs limits the generalizability of findings and the application of PRSs in non-European (especially African) populations 80 . Therefore, a broader representation of ancestries in CRC GWASs is necessary.
Studies of somatic genomic alterations in cancer have mostly focused on the coding genome, and identification of noncoding drivers has been challenging 73 . Yet, noncoding somatic driver mutations or focal amplifications in regulatory regions affecting expression have been reported for MYC 72 , TERT 73 and KLF5 (ref.
31
). The observed overlap between GWAS-identified CRC risk loci and somatic driver regions strongly suggests that expanding the search of somatic driver mutations to noncoding regulatory elements will yield additional discoveries and that searches for somatic drivers can be guided by GWAS findings.
Additionally, we found loci near proposed drug targets, including CHD1, which is implicated by the rare variant signal, and KLF5. So far, cancer drug target discovery research has almost exclusively focused on properties of cancer cells, yielding drugs targeting proteins that are either highly expressed or expressed in a mutant form due to frequent recurrent somatic missense mutations (for example, BRAF p.Val600Glu) or gene fusion events. In stark contrast with other common complex diseases, cancer GWAS results are not being used extensively to inform drug target selection. It has been estimated that selecting targets supported by GWAS could double the success rate in clinical development 81 . Our discoveries corroborate that GWAS results can considerably inform drug discovery, not only for treating cancers but also for chemoprevention in high-risk individuals.
In summary, in the largest genome-wide scan for sporadic CRC risk thus far, we identified the first rare variant signal for sporadic CRC, and almost doubled the number of known association signals. Our findings provide a substantial number of new leads that may spur downstream investigation into the biology of CRC risk, and that will influence drug development and clinical guidelines, such as personalized screening decisions.
URLs. EPACTS, https://genome.sph.umich.edu/wiki/EPACTS; ENCODE data processing pipeline, https://github.com/kundajelab/ atac_dnase_pipelines; WashU Epigenome Browser, https://epigenomegateway.wustl.edu. The PRS was constructed using the 95 known and newly discovered variants. The horizontal line represents the recommended age for first endoscopy for a person with average risk using the current screening guidelines for CRC. The risk threshold to determine the age for the first screening was set as the average of 10-year CRC risks for a 50-year-old man (1.25%) and woman (0.68%) who have not previously received an endoscopy. Details are in Methods.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41588-018-0286-6. 17 , we included 3,026 cases and 2,268 controls of East Asian ancestry to increase power for discovery. The stage 2 meta-analysis comprised newly generated genotype data involving four genotyping projects and 22 studies. After QC, the stage 2 meta-analysis included 23,262 cases and 38,296 controls, which were all of European ancestry. Studies, sample selection and matching are described in Supplementary Note. Supplementary Table 1 provides details on sample numbers and demographic characteristics of study participants. All participants provided written informed consent, and each study was approved by the relevant research ethics committee or institutional review board. Four normal colon mucosa biopsies for ATAC-seq were obtained from patients with a normal colon at colonoscopy at the Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Spain. Patients signed informed consent, and the protocol was approved by the Bellvitge Hospital Ethics Committee (Colscreen protocol PR084/16).
Whole-genome sequencing. We performed low-pass WGS of 2,192 samples from five studies at the University of Washington Northwest Genomics Center (Seattle, WA, USA). Cases and controls were processed and sequenced together. Libraries were prepared with ThruPLEX DNA-seq kits (Rubicon Genomics) and paired-end sequencing was performed using Illumina HiSeq 2500 sequencers. Reads were mapped to human reference genome (GRCh37 assembly) using Burrows-Wheeler aligner BWA v0.6.2 (ref. 82 ). Fold genomic coverage averaged 5.3× (range: 3.8-8.6× ). We used the GotCloud population-based multisample variant calling pipeline 83 for post-processing of BAM files with initial alignments, and to detect and call single-nucleotide variants and short indels. After removing duplicated reads and recalibrating base quality scores, QC checks included sample contamination detection. Variants were jointly called across all samples. To identify high-quality sites, the GotCloud pipeline performs a two-step filtering process. First, lower quality variants are identified by applying individual variant quality statistic filters. Next, variants failing multiple filters are used as negative examples to train a support vector machine classifier. Finally, we performed a haplotype-aware genotype refinement step via Beagle 84 and ThunderVCF 85 on the support vector machine-filtered VCF files. After further sample QC, we excluded samples with estimated DNA contamination > 3% (n = 16), duplicated samples (n = 5) or related individuals (n = 1), sex discrepancies (n = 0), and samples with low concordance with GWAS array data (n = 11). We checked for ancestry outliers by performing principal component analysis (PCA) after merging in data for shared, LD-pruned single-nucleotide variants for 1,092 individuals from the 1000 Genomes Project 86 . After QC, sequences were available for 1,439 CRC cases and 720 controls of European ancestry.
GWAS genotype data and quality control. Details of genotyping and QC for studies included in the stage 1 meta-analysis are described elsewhere 13, 18, 22 . Supplementary Table 1 provides details of genotyping platforms used. Before association analysis, we pooled individual-level genotype data of all stage 1 studies for a subset of SNPs to enable identification of unexpected duplicates and close relatives. We calculated identity by descent for each pair of samples using KINGrobust 87 and excluded duplicates and individuals that were second-degree or more closely related. As part of stage 2, 28,805 individuals from 19 studies were newly genotyped on a custom Illumina array based on the Infinium OncoArray-500K 26 and a panel of 15,802 successfully manufactured custom variants (described in Supplementary Note). An additional 8,725 individuals from five studies were genotyped on the Illumina HumanOmniExpressExome-8v1-2 array. Genotyping and calling for both projects were performed at the Center for Inherited Disease Research (CIDR) at Johns Hopkins University. Genotypic data that passed initial QC at CIDR subsequently underwent QC at the University of Washington Genetic Analysis Center (UW GAC) using standardized methods detailed in Laurie et al. 88 . The median call rate for the custom Infinium OncoArray-500K data was 99.97%, and error rate estimated from 301 sample duplicate pairs was 9.99 × 10 . A relatively low number of samples (n = 246) had a missing call rate > 2%, with the highest being 3.48%, and were included in analysis. For the HumanOmniExpressExome-8v1-2 data, median call rate was 99.96%, and the error rate estimated from 179 sample duplicate pairs was 2.65 × 10 . Some 30 samples had a missing call rate > 2%, with the highest being 3.79%, and were included in analysis. We excluded samples with discrepancies between reported and genotypic sex based on X chromosome heterozygosity and the mean values of sex chromosome probe intensities, unintentional duplicates, and close relatives, defined as individuals that are second-degree or more closely related. After further excluding individuals of non-European ancestry as determined by PCA (see below), the custom OncoArray data included in analysis comprised 11,852 CRC cases and 11,895 controls, and the HumanOmniExpressExome-8v1-2 array data included in analysis comprised 4,439 CRC cases and 4,115 controls. Only variants passing QC were used for imputation. We excluded variants failing CIDR technical filters or UW GAC quality filters, which included missing call rate > 2%, discordant calls in sample duplicates, and departures from Hardy-Weinberg equilibrium (HWE) (P < 1 × 10 −4 ) based on European-ancestry controls. The stage 2 analysis also included genotype data from the CORSA study (Supplementary Note). In total, 2,354 individuals were genotyped using the Affymetrix Axiom GenomeWide Human CEU 1 Array. We called genotypes using the AxiomGT1 algorithm. All samples had missing call rate < 3%. We excluded samples with discrepancies between reported and genotypic sex (n = 20), close relatives, defined as individuals that are second-degree or more closely related (n = 94), as inferred using KINGrobust 87 , and individuals of non-European ancestry (n = 6) as inferred from PCA. After QC, data included in analysis comprised 1,460 cases and 774 controls. Before phasing and imputation, we filtered out SNPs with missing call rate > 2%, or HWE P < 1 × 10 −4 . Imputed genotype data were obtained from UK Biobank and QC and imputation are described elsewhere 89 . A nested case-control data set was constructed as described in Supplementary Note. We excluded individuals of nonEuropean ancestry as inferred from PCA, and randomly dropped one individual from each pair that were more closely related than third-degree relatives as inferred using KING-robust. This led to excluding 137 samples. In total, 5,356 CRC (n = 5,004) or advanced adenoma (n = 352) cases and 21,407 matched controls were included in the replication analysis.
Principal component analysis.
After excluding close relatives, we performed PCA using PLINK1.9 (ref. 90 ) on LD-pruned sets of autosomal SNPs obtained by removing regions with extensive long-range LD 91, 92 , SNPs with MAF < 5%, HWE P < 1 × 10
, or any genotype missingness, and carrying out LD pruning using the PLINK option "-indep-pairwise 50 5 0.2. " To identify population outliers we merged in 1,092 individuals from 1000 Genomes Project Phase III and performed PCA using the intersection of variants 93 .
Genotype imputation. The 2,159 whole-genome sequences described above were used to create a phased imputation reference panel. After estimating haplotypes for all GWAS array data sets using SHAPEIT2 (ref. 94 ), we used minimac3 (ref.
95
) to impute from this reference panel (19.6 million variants with MAC > 1) into the GWAS data sets described above. We also imputed to the Haplotype Reference Consortium (HRC) panel 25 (39.2 million variants) using the University of Michigan Imputation Server 95 . To improve imputation accuracy for stage 1 data sets, phasing and imputation were performed after pooling studies or genotyping projects that used the same, or very similar, genotyping platforms (Supplementary Table 1 ). For stage 2, we performed phasing and imputation separately for each genotyping project data set and imputed to the HCR panel.
Statistical analyses.
Association testing of sequence data. We tested variants with MAC ≥ 5 for CRC association using Firth's bias-reduced logistic regression as implemented in EPACTS (see URLs) and adjusted for sex, age, study and three principal components calculated from an LD-pruned set of genotypes. We performed rare variant aggregate tests at the gene and enhancer level using the Mixed effects Score Test (MiST) 96 . This unified test is a linear combination between unidirectional burden and bidirectional variance component tests that performs best in terms of statistical power across a range of architectures 97 .
Association and meta-analysis. Stage 1 comprised two large mega-analyses of pooled individual-level genotype data sets (Supplementary Table 12 ). The four stage-2 genotyping project data sets were analyzed separately. Within each data set, variants with an imputation accuracy r 2 ≥ 0.3 and MAC ≥ 50 were tested for CRC association using the imputed genotype dosage in a logistic regression model adjusted for age, sex and study or genotyping project-specific covariates, including principal components to adjust for population structure (Supplementary Table 12 ). To account for residual confounding within CORSA, we tested association with each variant using a linear mixed model and kinship matrix calculated from the data, as implemented in EMMAX 98 . To enable meta-analysis, we then calculated approximate allelic log[OR] estimates and corresponding standard errors as described in Cook et al. 99 . Next, we combined association summary statistics across analyses via fixedeffects inverse variance-weighted meta-analysis. Because Wald tests can be notably anti-conservative for rare variant associations, we also performed likelihood ratio-based tests, followed by sample-size weighted meta-analysis, as implemented in METAL 100 . In total, 16,900,397 variants were analyzed. To examine residual population stratification, we inspected quantile-quantile plots of test statistics ( Supplementary Fig. 8 ) and calculated genomic control inflation statistics (λ GC ). λ GC for the combined meta-analysis was 1.105, and for stage 1 and stage 2 metaanalyses was 1.071 and 1.075, respectively. Because λ GC increases with sample size for polygenic phenotypes, even in the absence of confounding biases 101 , we investigated the effect of confounding due to residual population stratification using LD score regression 102 . Because of limitations of LD score regression, this analysis is restricted to common variants (MAF ≥ 1%) for which λ GC was 1.188 in the combined meta-analysis. The LD score regression intercept was 1.067, which is substantially less than λ GC , indicating at most a small contribution of bias and that inflation in χ 2 statistics results mostly from polygenicity. We also calculated λ 1,000 , which is the equivalent inflation statistic for a study with 1,000 cases and 1,000 controls 103 . For the combined meta-analysis, λ 1000 was 1.004 and for both stage 1 and stage 2 meta-analyses it was 1.003.
Significance threshold for the replication genotyping experiment. To protect against probe design failure, we built redundancy into the custom genotyping panel by including LD proxies of independently associated variants selected for follow-up. To determine the number of independent tests, we performed LD clumping of the 9,198 analyzed variants that were selected for replication genotyping based on the stage 1 meta-analysis, and that survived filters described above. Using an r 2 threshold of 0.1 this translated to 6,438 independent tests and a Bonferroni significance threshold of 0.05/6,438 = 7.8 × 10 −6
.
Conditional and joint multiple-variant analysis.
To identify additional distinct association signals at CRC loci, we performed a series of conditional metaanalyses. At each locus attaining P < 5 × 10
, we included the genotype dosage for the variant showing the strongest statistical evidence for association in the region in the combined meta-analysis, as an additional covariate in the respective logistic regression models. Association summary statistics for each variant in the region were then combined across studies by a fixed-effects meta-analysis. If at least one association signal attained a significance level of P < 1 × 10 −5 in this meta-analysis, we performed a second round of conditional meta-analysis, adding the variant showing the strongest statistical evidence for association in the region in the first round of conditional meta-analysis as a covariate to the logistic regression models used in the first round. We repeated this procedure and kept adding variants to the model until no additional variants at the locus attained P < 1 × 10
. Finally, we performed a joint multiple-variant analysis in which we jointly estimated the effects of variants selected in each step and tested for each variant whether the P value from the joint multiple-variant analysis (P J ) was < 1 × 10
. Analyses were performed on 2-Mb windows centered on the most associated variant in the unconditional analysis. If windows overlapped, we performed the analysis on the collapsed genomic region. Because of extensive LD, we used a 4-Mb window for the MHC region.
Definition of known loci. We compiled a list of 62 previously reported genomewide significant CRC association signals from the literature (Supplementary Table 3 ). Because of improved power and coverage of our study, we identified the most associated variant at each signal, and used these lead variants for further analyses, rather than the previously reported index variant.
Refinement of association signals.
To refine new association signals, we constructed credible sets that were 99% probable, based on posterior probability, to contain the causal disease-associated SNP 104 . In brief, for each distinct signal, we retained a candidate set of variants by identifying all analyzed variants with r 2 ≥ 0.1 with the most associated variant within a 2-Mb window centered on the most associated variant. We calculated approximate Bayes' factors (ABFs) 105 for each variant as:
where r = 0.04/(s.e.
2 + 0.04), z = β/s.e., and β and s.e. are the log[OR] estimate and its standard error from the combined meta-analysis, respectively. For loci with multiple distinct signals, results are based on conditional meta-analysis, adjusting for all other index variants in the region. We then calculated the posterior probability of being causal as ABF/T where T is the sum of ABF values over all candidate variants. Next, variants were ranked in decreasing order by posterior probabilities and the 99% credible set was obtained by including variants with the highest posterior probabilities until the cumulative posterior probability was ≥ 99%.
Functional genomic annotation.
To nominate variants for future laboratory follow-up, we performed bioinformatic analysis at each new signal using our functional annotation database, and a custom University of California Santa Cruz (UCSC) analysis data hub. Using ANNOVAR 106 , we annotated lead variants and variants in LD (r 2 ≥ 0.4) with the lead variant, relative to features pertaining to: (1) Table 8 if they met any of the following conditions: DANN score ≥ 0.9, CADD phred score ≥ 20, Eigen-PC phred score ≥ 17, PolyPhen2 prediction of "probably damaging, " stop-loss, stop-gain, or splicing variant, or positioned in a predicted regulatory element. We visually inspected loci overlapping with CRC-relevant functional genomic annotations. Variants positioned in enhancers with aberrant CRC activity were identified by comparing epigenomes of nondiseased colorectal tissues or colonic crypt cells to epigenomes of primary CRC cell lines. We prioritized target genes for loci with predicted regulatory function. Evidence suggests that topological association domains can be used to map physical boundaries on gene promoter interactions with distal regulatory elements [114] [115] [116] . As such, we used GM12878 Hi-C Chromosome Conformation Capture data to identify gene promoters that were in the same topological association domains as risk loci using the WashU Epigenome Browser (see URLs). Genes in this list were further prioritized based on biological relevance and expression quantitative trait loci data from GTEx 117 using HaploReg v4.1 (ref. 118 ).
Assay for transposable-accessible chromatin using sequencing. We generated high-resolution maps of DNA-accessible regions in normal colon mucosa samples using ATAC-seq. Using the updated omni-ATAC protocol for archival samples, we performed ATAC-seq in four colon mucosa biopsies from the Catalan Institute of Oncology (ICO)-biobank taken from participants undergoing screening at IDIBELL, Spain. Biopsies were cryopreserved by slow freezing using a solution of 10% dimethylsulfoxide, 90% medium and Mr. Frosty Cryo 1 °C Freezing Containers (Thermo Scientific). ATAC-seq was implemented as prescribed with two exceptions. Instead of Dounce homogenizer, we used a tissue lyser and stainless bead system, pulverizing at 40 Hz for 2 min and pulsing at 50 Hz for 10-20 s. Secondly, Illumina library quantification was performed using picogreen quantitation and TapeStation instead of KAPA quantitative PCR. Libraries were sequenced to an average of 25 million paired end reads using Illumina HiSeq 2500. The ENCODE data processing pipeline was implemented (see URLs) aligning to hg19 (ref.
119
). QC results are summarized in Supplementary Table 14 .
Regulatory and functional information enrichment analysis. We used GARFIELD 74 to identify cell types, tissues and functional genomic features relevant to CRC risk. This method tests for enrichment of association in features primarily extracted from ENCODE and Roadmap Epigenomics Project data, while accounting for confounding variables, including LD. We applied default settings and used the author-supplied data, which are suitable for analysis of GWAS results based on individuals of European ancestry.
Pathway and gene set enrichment analysis. We used MAGENTA to test predefined gene sets (for example, KEGG pathways) for enrichment for CRC risk associations 75 . We used combined meta-analysis results as input and applied default settings, which included removing genes that fall in the MHC region from analysis. Enrichment was tested at two gene P-value cutoffs: the 95th and 75th percentiles of all gene P values in the genome.
Estimation of contribution of rare variants to heritability. We used the LD-and MAF-stratified component GREML (GREML-LDMS) method as implemented in GCTA 76 to estimate the proportion of variation in liability for CRC explained by all imputed autosomal variants (that is, estimate of narrow-sense heritability h g 2 ), and the proportion contributed by rare variants (MAF ≤ 1%). Because of computational limitations we analyzed a subset of 11,895 cases and 14,659 controls imputed to our WGS panel. We analyzed individual-level data for 17,649,167 imputed variants with MAC > 3 and HWE test P ≥ 10 −6
. Following Yang et al. 76 , we did not filter based on imputation quality. In brief, we stratified variants into groups based on MAF (boundaries at 0.001, 0.01, 0.1, 0.2, 0.3 and 0.4) and mean LD score (boundaries at quartiles) calculated as described in Yang et al 76 . We then calculated genetic relationship matrices for each of these 28 variant partitions and jointly estimated variance components for these partitions, adjusting for age, sex, study, genotyping batch and three genotype prinicipal components. From the variance component estimates and their variance-covariance matrix we estimated the contribution of rare variants (MAF ≤ 1%) and common variants (MAF > 1%), and calculated standard errors using the delta method. We tested significance of the contribution of rare variants using a likelihood ratio test. To calculate heritability on the underlying liability scale we interpreted K as lifetime risk 120 and used an estimate , where p i is the risk allele frequency for variant i, q i = 1 -p i , and r i is the estimated per-allele OR 9, 121 . We adjusted the OR estimates of new association signals for the winner's curse following Zhong and Prentice 78 . We represented previously identified association signals by the variant showing the strongest statistical evidence of association in the combined meta-analysis, and assumed that the winner's curse was negligible. We assumed λ 0 to be 2.2 (ref. 122 ). Using the delta method, we computed the variance for the proportion of familial RR as follows: 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested 
Software and code
Policy information about availability of computer code
Data collection
No software was used to collect data.
Data analysis
Genotype calling for new genotyping projects was performed using Illumina's GenomeStudio version 2011.1, Genotyping Module v1.9.4, GenTrain v 1.0 algorithm, and Affymetrix Power Tools version 1.18.2 and the AxiomGT1 algorithm. Alignment of whole-genome sequence reads was performed using BWA v0.6.2 and variant calling using the GotCloud pipeline, which uses Beagle and ThunderVCF. Software used for genotyping quality control included PLINK1.9, KING 2.0.9, and the R package GWASTools. Phasing and imputation were performed using SHAPEIT2 and minimac3, respectively. Imputation to the Haplotype Reference Consortium panel was performed using the University of Michigan Imputation Server. Association analyses were performed using R, EPACTS v3.3.0, and METAL. Variant annotation was performed using ANNOVAR. Gene prioritization was performed using HaploReg v4.1. Functional and pathway enrichment analyses were conducted using GARFIELD v2 and MAGENTA v2. ATAC-Seq peak calling was performed using the ENCODE pipeline. Heritability analyses were performed using the GCTA package version 1.25.2. LD score regression was performed using ldsc version 1.0.0. The familial relative risk explained and risk prediction calculations were performed using R.
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All whole-genome sequence data have been deposited at the database of Genotypes and Phenotypes (dbGaP), which is hosted by the U.S. National Center for Biotechnology Information (NCBI), under accession number phs001554.v1.p1. All custom Infinium OncoArray-500K array data for the studies in the Stage 2 metaanalysis have been deposited at dbGaP under accession number phs001415.v1.p1. All Illumina HumanOmniExpressExome-8v1-2 array data for the studies in the Stage 2 meta-analysis have been deposited at dbGaP under accession number phs001315.v1.p1. Genotype data for the studies included in the Stage 1 metaanalysis have been deposited at dbGaP under accession number phs001078.v1.p1. The UK Biobank resource was accessed through application number 8614.
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Sample size
This work used newly generated whole-genome sequencing data (WGS; n=2,159), and existing and newly generated GWAS data on colorectal cancer (CRC; total n=125,478). Both datasets comprise the largest and most comprehensive to date. Rationale for the WGS study design which balanced sample size and sequencing coverage, is detailed under Study Overview in the Results section of the article. No sample size calculations were performed for the GWAS meta-analysis. We attempted to include as many studies as possible in the meta-analysis to maximize statistical power for discovery. Given that we almost doubled the sample size compared to the previous largest CRC GWAS metaanalysis, and the improved and more comprehensive genotype imputation, we expected to have substantially higher statistical power to detect variants with smaller effect sizes or low minor allele frequencies.
Data exclusions We excluded samples and variants, using standardized methods and predefined filtering criteria to remove unreliable genotype calls or problematic samples, as described in the Online Methods. Sample exclusions included samples with evidence of DNA contamination, samples with high missing genotype rates, unintentional duplicate pairs, sex discrepancies, and closely related individuals. To avoid confounding due to population stratification, we excluded ancestry outliers identified through principal components analysis. Variants were excluded according to predefined quality controls filtering criteria as detailed in the Online Methods. For the WGS dataset this involved quality filtering based on a support vector machine (SVM) classifier; for the genotype array data, this included missing call rate filters, Hardy-Weinberg equilibrium, and various technical filters. Imputed genotype data were filtered on imputation quality and minor allele count.
Replication
We present two sets of results: 1) new association signals for CRC risk that replicate (i.e., attain a Bonferroni significance threshold) in our independent custom replication genotyping experiment, and 2) new association signals for CRC risk based on all available data. Since 2) is based on the largest CRC GWAS dataset (>125,000 individuals), a well-powered replication dataset is currently not available.
Randomization To limit potentially confounding experimental batch effects, we sequenced and genotyped cases and controls together and randomized samples across flow cells or plates. Likewise, variant calling, phasing and imputation were performed for cases and controls together. Since this is an observational genetic association study, randomization to experimental groups is not relevant.
Blinding
The laboratories conducting the sequencing or genotyping did not have access to phenotype data. Genotype calling was also blinded with respect to case-control status.
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